Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of topical heparin for palmar-plantar erythrodysaesthesia associated with capecitabine
2009-018171-13Phase 2Active
- Sponsor
- OncoSur
- Start
- Feb 2010
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of heparin in Erythrodysesthesia syndrome (PPE), sponsored by OncoSur. Primary endpoint: Clinical improvement at three weeks. Started Feb 2010; status: active.
02
Drugs
heparin
03
Conditions
Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on 2009-018171-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018171-13.